We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 1BSX market cap is 105.85B. The company's latest EPS is USD 1.0679 and P/E is 72.20.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 10.77B | 10.01B | 11.89B | 12.68B | 14.35B |
| Operating Income | 1.52B | -79M | 984M | 1.67B | 2.34B |
| Net Income | 4.7B | -115M | 985M | 642M | 1.57B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 30.57B | 30.78B | 32.23B | 32.47B | 35.14B |
| Total Liabilities | 16.69B | 15.45B | 15.61B | 14.9B | 15.61B |
| Total Equity | 13.88B | 15.33B | 16.62B | 17.57B | 19.53B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 1.84B | 1.51B | 1.87B | 1.53B | 2.5B |
| Investing | -5.04B | -411M | -1.6B | -2.01B | -2.57B |
| Financing | 2.97B | 293M | -95M | -548M | 5M |
| Market Cap | 105.85B |
| Price to Earnings Ratio | 72.20 |
| Price to Sales Ratio | 7.9 |
| Price to Cash Ratio | 131.03 |
| Price to Book Ratio | 5.8 |
| Dividend Yield | - |
| Shares Outstanding | 1.47B |
| Average Volume (1 week) | 44 |
| Average Volume (1 Month) | 64 |
| 52 Week Change | 44.29% |
| 52 Week High | 73.50 |
| 52 Week Low | 49.90 |
| Spread (Intraday) | 0.5 (0.69%) |
| Company Name | Boston Scientific Dl 01 |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.bostonscientific.com |
| Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
